Answers are grounded in this paper and cite their sources.
Mazdutide is a once-weekly dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that has demonstrated promising effects on body weight and metabolic parameters in adults with overweight or obesity. However, available evidence varies in dose, treatment duration, and study population. We aimed to provide an updated assessment of the efficacy and safety of mazdutide, focusing primarily on changes across specific treatment endpoints. We systematically searched PubMed, Cochrane Library, Scopus, and Web of Science (WOS) from inception to 1 September 2026 for randomized controlled trials (RCTs) evaluating mazdutide in adults with overweight or obesity. The primary outcomes were percentage change in body weight and change in waist circumference. Outcomes were pooled separately at prespecified treatment endpoints of weeks 12, 16, 20, 24, 32, and 48 rather than as a single overall estimate. Random-effects models were fitted using restricted maximum likelihood with Hartung–Knapp adjustment. Dose arms within each trial were combined for the primary and secondary analyses to avoid double-counting shared placebo participants. Three-level meta-regression with cluster-robust variance estimation was used to account for multiple effect estimates contributed by individual trials. Dose–response analyses were additionally performed at week 12 and using an arm-level three-level model. A sensitivity analysis excluded the single trial that enrolled participants with type 2 diabetes, and the certainty of evidence was rated with GRADE. Across eight included RCTs (1,670 randomized participants, 87% from trials conducted in China), mazdutide produced significantly greater reductions in body weight than placebo at all prespecified endpoints: −7.82% at week 12, − 9.91% at week 16, − 12.12% at week 20, − 11.20% at week 24, − 13.78% at week 32, and − 15.76% at week 48. Waist circumference was also reduced significantly, by − 5.15 cm at week 12, − 5.72 cm at week 16, − 7.38 cm at week 24, − 10.33 cm at week 32, and − 10.70 cm at week 48. Estimates were unchanged when the trial enrolling participants with type 2 diabetes was excluded. In exploratory meta-regression, treatment exposure was associated with greater weight reduction (β = −0.22% per week; 95% CI, − 0.375 to − 0.066; P = 0.021), whereas the arm-level dose–response association was smaller and not statistically significant (β = −0.47% per 1-mg increase; 95% CI, − 1.15 to 0.20; P = 0.083); these analyses rest on eight trials and are hypothesis-generating. Mazdutide also improved HbA1c, fasting plasma glucose, blood pressure, total cholesterol, LDL-C, triglycerides, and serum uric acid, while changes in HDL-C and ALT were not statistically significant. Gastrointestinal adverse events were more frequent with mazdutide, particularly vomiting (36.5% vs. 2.5%; RR, 9.82), nausea (42.5% vs. 6.6%; RR, 5.48), decreased appetite (RR, 3.83), and diarrhea (RR, 2.91). Serious adverse events were not significantly increased, whereas discontinuation because of adverse events was infrequent but more common with mazdutide (2.9% vs. 0.4%). The certainty of evidence was moderate to high for body weight and waist circumference. Mazdutide produced clinically meaningful reductions in body weight and waist circumference that increased progressively with treatment duration; the relative contributions of dose and duration could not be separated with confidence from the available trials. Hemodynamic and metabolic parameters also improved, including glycemic measures, total cholesterol, LDL-C, triglycerides, and serum uric acid, whereas gastrointestinal adverse events (AEs) were the main safety concern. Further larger trials in ethnically diverse and older populations are warranted to confirm durability, optimize dosing, and establish long-term safety.
No takes yet. Share an insight, caveat, or question.
Shaltout et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: